Selected Deals Done by MP Advisors

1. An Introduction
www.mpadvisor.com
1

2. MP Advisors – Who We Are
 Tracks Only Global Bio-Pharma Industry, Since 1996
• We don’t do anything other than Bio Pharmaceutical sector.
• An active rapport with industry, finance and regulators help us forecast
future trends
• The outcome is - providing superior strategy and investment advisory
services to the global biopharma industry Assists BD team of Biopharma
companies across US, EU & Asia to accomplish its wish list.
• Private Equity (PE) and Pension fund managers seek consultation to
understand fundamentals of industry/sector/geography/company.
2

3. What We do ?
• Institutional Investment Advisory:
• We advise our global fund manager clients for investments in bio pharma
stocks on the basis of our fundamental research of the company and the
sector.
• All our fundamental analysis culminates in our annual flagship
“Outlook” report.
• Strategic Advisory:
• Global advisor for pharmaceutical company in M & A as well as
forecasting strategic Investment/divestment opportunities in the near
future.
3

4. Selected List of Deals by MP Advisors
 2011 – Evaluated strategic options for a CRAM company having operations in EU and Asia.
 2011 – Evaluated a Formualtion Contract Research Organisation on behalf of a global PE investor.
 2010 - Acted as sole advisor to Intas Biopharmaceuticals, a EMEA approved company producing
Biosimilar, to raise private equity funding from TATA Capital
 2009 – Sell side banker to Bangalore Genei, a Biologic company of Sanmar group, Merck KgA,
Germany acquired.
 2009 – Parabolic Drugs Ltd shares to BTS Advisors/ Swiss Tech PE
 2008 – MP conceptualized innovator-generic hybrid model and was strategic advisor to Daiichi-Sankyo
who bought conttolling stake in Ranbaxy.
 2008 – Sold Tonira Pharma, only API company in India who earns half its revenue from Japan, to
IPCA.
4

5. Selected List of Deals by MP Advisors
 2008 - Acquired an API company in Austria (Loba Chemie) for South India based listed company
(Shilpa Medicare)
 2008 - Raised INR 200m for Marck Bioscience, a company specializing in Sterile products from a PE
 2007 – Drug Royalty - Assessed market potential of ~a dozen products up to 2015 on behalf of an
investor who looks at the royalty income stream
 2006 – Conducted due-diligence on behalf of USV, an Indian company wanting to acquire a Bio-
Similar company in Ireland (Genmedix later acquired by Reliance Life Sciences).
 2006 - Advised an EU company BioMerieux in deciding the ranking of different SBU’s of an Indian
company, Shantha Biotech, it acquired
 2006 - A US based NCE company (Cempra Pharmaceuticals) to source API for the NCE from an
Indian company (Alembic).
 2005 - Advised an Indian conglomerate (Atul Ltd) to speed up its pharma division growth.
5

6. Selected List of Deals by MP Advisors
 2004 - Advised one of the top 10 MNC w r t global entry of Vaccine and Insulin business.
 2004 -Generated binding bid for an Indian OTC company (Paras Pharma) from an EU company.
 2004 - Divested brands of a leading EU company, Solvay in India as part of its global strategy to Indoco
Remedies (Karvol) and Alembic Pharmaceuticals (Yutopar).
 2002 - Led first investment in a discovery based US biotech company, Onconova (Philadelphia) by an
Indian company Cadila.
 2001 – Sold 35% stake in German Remedies Ltd. Held by four German companies i.e. Asta Medica
(Degussa Hull co), Boehringer Ingelheim, Schering AG & Dr. Falke. Aggressive bidding was undertaken by
Pharmacia, Bristol-Myers Squibb & Cadila.
 2001 - Represented an EU company AstraZeneca to buy out its Indian partner, Astra-IDL (A Hinduja
Group Company).
 2000- Established JV between a German (Altana) & an Indian company (Cadila) to produce an “on patent”
API (pantaprazole) for global need.
 1996 - Licensed out the 1st Indian NCE (Glitazone PhI )from Dr. Reddy’s to an EU company, Novo
6
Nordisk.

7. Selected List of Deals by MP Advisors
7

8. MP Advisors
Bios of Employees
8

9. MP Advisors – CV of Employees
• Tarun Shah, MBA, is the founder of MP Advisors. He brings 25 years of global experience in
Corporate Finance and Investment Banking. He has significantly influenced the evolution of
cross border M&A activities in the pharmaceutical industry in recent years, having
conceptualized some of the important transactions as the major companies across the world
accelerate their efforts to create new business models in synchronization with the changing
times. Tarun has spotted novel investment (and divestment) ideas for Companies whether Small
or Big, Biotech or Generics, Private or Public, G8, BRIC or Emerging markets . Fifteen
professionals working at MP Advisors have education in Pharmacy or Biochemistry or
Medicine and/or Finance, work experience as a Regulatory, R&D, marketing or IP. The senior
team members are with the company from ~ its inception.
9

10. MP Advisors – CV of Employees
• Devesh Singh, Pharmacist, MBA, After graduating with a degree in pharmacology from India,
Devesh worked as Medical Representative with Novartis and Purdue, in India. He later earned a
MBA from Stuttgart-IMT, Germany worked with IMI Consulting GmbH and Abbott GmbH.
He returned to India in 2006 and joined MP Advisors.
• Vrunda Shah, CFA, MS (Finance), has two years of work experience in academic research at
ICFAI University for the examinations department and has also undergone an internship
program with Cygnus Business Consulting & Research. Successfully completed projects on
research and valuation, covering analysis of company performance on all financial parameters.
She has written articles for the Portfolio Organizer Magazine. At MP Advisors, she is a part of
the Japan pharma team.
10

11. MP Advisors – CV of Employees
• Subita Srimal, Ph.D., founded a pharmaceutical company (now dormant) that manufactured a
diagnostic reagent, Carcinoscorpious amebocyte lysate (CAL) used for the detection of pyrogens.
CAL has been developed solely through her efforts. Subita is a member of MP’s scientific think
tank, and is responsible for providing scientific evaluation of the industry R&D pipeline for our
investment decisions. Subita received her postdoctoral training at Prof Iwanaga’s lab in Kyushu
University (Japan in 1984) and at Prof Carl Nathan’s lab, Cornell University Medical College in New
York (1987-1990). Previously, she worked at Tata Institute of Fundamental Research, Mumbai and
Indian Institute of Science, Bangalore as well as headed her own lab at Institute of Microbial
technology, Chandigarh. Subita has several publications and patents to her credit.
• Sanjeev Mishra, B. Sc., MBA, works with Subita. His skills in Science and Finance helps assiging
risk reward ratio of a R&D compound and/or a company.
• Khyati Thakrar, M.Sc. (Microbiology), She has participated in a project at Bhabha Atomic
Research Center, Mumbai, on Cloning & Expression of mutant of uvrA gene (DC32) in
Haemophillus influenza. Prior to joining MP, she worked with Astral Pharmaceutica, a US FDA
approved company producing Ceph and Penincillin based sterile products.
11

12. MP Advisors – CV of Employees
• Nimish Mehta, CFA is responsible for staying on top of changes in Generics
industry, globally. Indian companies are becoming signficant global generics
players. Nimish keeps track of US, German, China, India and Japan generics
companies.
• Manushi Naik, M.Sc Microbiology and Advanced Diploma in IPR & Regulatory
Affairs from MS University. She has begun her career with the MP team where she
is working as a member of the Indian pharma sector.
• Vivek Agarwal, B. Sc., CFA (CFA Institute, cleared all 3 levels) is helping Mr.
Nimish Mehta in actively covering Indian Pharma Industry. He has completed his
B.Sc in Life Science.
12

13. MP Advisors – CV of Employees
• Vishal Manchanda, B.E. MBA tracks large pharma companies operating from US
and Europe. As an Engineer, he looks at clinical data, unemotionally to predict future
of R&D pipeline of large companies. He has developed a good neck on the job,which
he is doing since 2006.
• Vijayakannan R., M.Pharm, PhD. His two years experience in formulation
development in the pharmaceutical industry and five years of University research has
familiarized him with all aspects of drug discovery, development and approval
processes. His M.Pharm and Doctorate is in Medicinal & Pharmaceutical Chemistry
He has several national and international publications to his credit.
• Ripple Mehta, B. Pharmacy, MBA, has worked with Dr. Reddy’s and Astra Zeneca
in Brand Management & Marketing prior to joining MP Advisors in 2007. She has
good understanding of competitive landscape of most of the therapy and very good
insight of behavior of physicians and dispensing pharmacist.
13